

---

# Contents

<i>Preface</i> . . . . .	v
<i>Contributors</i> . . . . .	xiii
PART I MANIPULATION AND MODIFICATION OF IMMUNE CELLS: DENDRITIC CELLS	
1 Single-Step Antigen Loading and Maturation of Dendritic Cells Through mRNA Electroporation of a Tumor-Associated Antigen and a TriMix of Costimulatory Molecules . . . . .	3
<i>Daphné Benteyn, An M.T. Van Nuffel, Sofie Wilgenhof, and Aude Bonehill</i>	
2 Generation of Multiple Peptide Cocktail-Pulsed Dendritic Cells as a Cancer Vaccine . . . . .	17
<i>Hyun-Ju Lee, Nu-Ri Choi, Manh-Cuong Vo, My-Dung Hoang, Youn-Kyung Lee, and Je-Jung Lee</i>	
3 Pulsing Dendritic Cells with Whole Tumor Cell Lysates . . . . .	27
<i>Laura Alaniz, Manglio M. Rizzo, and Guillermo Mazzolini</i>	
4 Antigen Trapping by Dendritic Cells for Antitumor Therapy . . . . .	33
<i>Chiranjib Pal</i>	
5 Ex Vivo Loading of Autologous Dendritic Cells with Tumor Antigens . . . . .	41
<i>Manglio M. Rizzo, Laura Alaniz, and Guillermo Mazzolini</i>	
6 Tumor Antigen-/Cytokine-Pulsed Dendritic Cells in Therapy Against Lymphoma . . . . .	45
<i>Sumit K. Hira, Deepak Verma, and Partha P. Manna</i>	
7 Dendritic Cells Primed with Protein-Protein Fusion Adjuvant . . . . .	57
<i>Liying Wang and Yongli Yu</i>	
8 Antigen-Specific mRNA Transfection of Autologous Dendritic Cells . . . . .	77
<i>Fabian Benencia</i>	
9 Electroporation of Dendritic Cells with Autologous Total RNA from Tumor Material . . . . .	87
<i>Francesca Milano and K.K. Krishnadath</i>	
10 Dendritic Cells Transfected with Adenoviral Vectors as Vaccines . . . . .	97
<i>Joseph Senesac, Dmitry Gabilovich, Samuel Pirruccello, and James E. Talmadge</i>	
11 Genetic Modification of Dendritic Cells with RNAi . . . . .	119
<i>Xiao-Tong Song</i>	

12 Fast Monocyte-Derived Dendritic Cell-Based Immunotherapy . . . . . 131  
*Gamal Ramadan*

13 Intratumoral Injection of BCG-CWS-Pretreated Dendritic Cells Following Tumor Cryoablation . . . . . 145  
*Naoshi Kawamura, Masaru Udagawa, Tomonobu Fujita, Toshiharu Sakurai, Tomonori Yaguchi, and Yutaka Kawakami*

14 Exploiting the CD1d-iNKT Cell Axis for Potentiation of DC-Based Cancer Vaccines . . . . . 155  
*Roeland Lameris, Famke L. Schneiders, Tanja D. de Gruijl, and Hans J. van der Vliet*

PART II MANIPULATION AND MODIFICATION OF IMMUNE CELLS:  
T LYMPHOCYTES AND NK CELLS

15 Modification of T Lymphocytes to Express Tumor Antigens . . . . . 169  
*Aaron E. Foster and Xiao-Tong Song*

16 Genetic Modification of Mouse Effector and Helper T Lymphocytes Expressing a Chimeric Antigen Receptor . . . . . 177  
*Liza B. John, Tess M. Chee, David E. Gilham, and Phillip K. Darcy*

17 Genetic Modification of Cytotoxic T Lymphocytes to Express Cytokine Receptors . . . . . 189  
*Serena K. Perna, Barbara Savoldo, and Gianpietro Dotti*

18 Monitoring the Frequency and Function of Regulatory T Cells and Summary of the Approaches Currently Used to Inhibit Regulatory T Cells in Cancer Patients . . . . . 201  
*Chiara Camisaschi, Marcella Tazzari, Licia Rivoltini, and Chiara Castelli*

19 Cytokine Activation of Natural Killer Cells . . . . . 223  
*Syh-Jae Lin, Pei-Tzu Lee, and Ming-Ling Kuo*

PART III MANIPULATION AND MODIFICATION OF TUMOR CELLS

20 Loading of Acute Myeloid Leukemia Cells with Poly(I:C) by Electroporation . . . . . 233  
*Eva Lion, Charlotte M. de Winde, Viggo F.I. Van Tendeloo, and Evelien L.J.M. Smits*

21 Autologous Tumor Cells Engineered to Express Bacterial Antigens . . . . . 243  
*Vijayakumar K. Ramiya, Maya M. Jerald, Patricia D. Lawman, and Michael J.P. Lawman*

22 Tumor Cell Transformation Using Antisense Oligonucleotide . . . . . 259  
*Mohamed R. Akl and Nehad M. Ayoub*

23 The Direct Display of Costimulatory Proteins on Tumor Cells as a Means of Vaccination for Cancer Immunotherapy . . . . . 269  
*Haval Shirwan, Esma S. Yolcu, Rajesh K. Sharma, Hong Zaho, and Orlando Grimany-Nuno*

## PART IV MANIPULATION OF IMMUNE/TUMOR INTERACTIONS

- 24 Cloning Variable Region Genes of Clonal Lymphoma Immunoglobulin for Generating Patient-Specific Idiotype DNA Vaccine . . . . . 289  
*Soung-chul Cha, Hong Qin, Ippei Sakamaki, and Larry Kwak*
- 25 Heat Shock Proteins Purified from Autologous Tumors Using Antibody-Based Affinity Chromatography. . . . . 305  
*Christian Kleist, Marco Randazzo, Janina Jiga, and Peter Terness*
- 26 Invariant Chain-Peptide Fusion Vaccine Using HER-2/neu . . . . . 321  
*Sonia A. Perez, George E. Peoples, Michael Papamichail, and Constantin N. Baxevanis*
- 27 TLR-9 Agonist Immunostimulatory Sequence Adjuvants Linked to Cancer Antigens . . . . . 337  
*Hidekazu Shiota and Dennis M. Klinman*
- 28 Production of Multiple CTL Epitopes from Multiple Tumor-Associated Antigens. . . . . 345  
*Rena Morita, Yoshihiko Hirohashi, Munehide Nakatsugawa, Takayuki Kanaseki, Toshihiko Torigoe, and Noriyuki Sato*
- 29 Preparation of Polypeptides Comprising Multiple TAA Peptides . . . . . 357  
*Bing Ni, Zhengcai Jia, and Yuzhang Wu*
- 30 Idiotype Vaccine Production Using Hybridoma Technology . . . . . 367  
*Susana Inoges, Ascensión López Díaz de Cerio, Helena Villanueva, Fernando Pastor, and Maurizio Bendandi*
- 31 Preparation of Cancer-Related Peptide Cocktails that Target Heterogeneously Expressed Antigens . . . . . 389  
*Reshu Gupta and Pradip P. Sachdeva*

## PART V DELIVERY MECHANISMS

- 32 Making an Avipoxvirus Encoding a Tumor-Associated Antigen and a Costimulatory Molecule. . . . . 407  
*Paul M. Howley, Kerrilyn R. Diener, and John D. Hayball*
- 33 Bacterial Vectors for the Delivery of Tumor Antigens . . . . . 429  
*Yan Wang, Bertrand Toussaint, and Audrey Le Gouëllec*
- 34 Preparation of Peptide Microspheres Using Tumor Antigen-Derived Peptides . . . . . 443  
*Santwana Bhatnagar, Raza Ali Naqvi, Riyasat Ali, and D.N. Rao*
- 35 Production of Antigen-Loaded Biodegradable Nanoparticles and Uptake by Dendritic Cells . . . . . 453  
*Vijaya Bharti Joshi, Sean M. Geary, and Aliasger K. Salem*
- 36 Development of Plasmid-Lipid Complexes for Direct Intratumoral Injection. . . . . 467  
*Rama P. Kotipatruni and Ganji Purnachandra Nagaraju*

PART VI THE ADVANCES, CHALLENGES, AND FUTURE OF CANCER VACCINES

37 The Use of Dendritic Cells for Peptide-Based Vaccination in Cancer Immunotherapy . . . . . 479  
*Mohamed L. Salem*

38 Advances in Host and Vector Development for the Production of Plasmid DNA Vaccines . . . . . 505  
*Juergen Mairhofer and Alvaro R. Lara*

39 Challenges Facing the Development of Cancer Vaccines . . . . . 543  
*Mayer Fishman*

40 Future of Cancer Vaccines . . . . . 555  
*Hauke Winter, Bernard A. Fox, and Dominik Rüttinger*

*Index* . . . . . 565



<http://www.springer.com/978-1-4939-0344-3>

Cancer Vaccines

Methods and Protocols

Lawman, M.J.P.; Lawman, P.D. (Eds.)

2014, XVIII, 569 p. 80 illus., 42 illus. in color., Hardcover

ISBN: 978-1-4939-0344-3

A product of Humana Press